Diabetic cardiomyopathy, a disorder of the heart muscle in diabetic patients, is one of the major causes of heart failure. Since diabetic cardiomyopathy is now known to have a high prevalence in the asymptomatic diabetic patient, prevention at the earliest stage of development by existing molecules would be appropriate in order to prevent the progression of heart failure. In this study, we investigated the protective role of multiple antioxidants (MA), on cardiac dysfunction and cardiac cell apoptosis in streptozotocin (STZ)-induced diabetic rat. Diabetic cardiomyopathy in STZ-treated animals was characterized by declined systolic, diastolic myocardial performance, oxidative stress and apoptosis in cardiac cells. Diabetic rats on supplementation with MA showed decreased oxidative stress evaluated by the content of reduced levels of lipid per-oxidation and decreased activity of catalase with down-regulation of heme-oxygenase-1 mRNA. Supplementation with MA also resulted in a normalized lipid profile and decreased levels of pro-inflammatory transcription factor NF-kappaB as well as cytokines such as TNF-α, IFN-γ, TGF-β, and IL-10. MA was found to decrease the expression of ROS-generating enzymes like xanthine oxidase, monoamine oxidase-A along with 5-Lipoxygenase mRNA and/or protein expression. Further, left ventricular function, measured by a microtip pressure transducer, was re-established as evidenced by increase in ±dp/dtmax, heart rate, decreased blood pressure, systolic and diastolic pressure as well as decrease in the TUNEL positive cardiac cells with increased Bcl-2/Bax ratio. In addition, MA supplementation decreased cell death and activation of NF-kappaB in cardiac H9c2 cells. Based on our results, we conclude that MA supplementation significantly attenuated cardiac dysfunction in diabetic rats; hence MA supplementation may have important clinical implications in terms of prevention and management of diabetic cardiomyopathy.
References
[1]
Jaffe AS, Spadaro JJ, Schechtman K, Roberts R, Geltman EM, et al. (1984) Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 108: 31–37.
[2]
Cai L (2006) Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 41: 851–861.
[3]
Cai L, Wang Y, Zhou G, Chen T, Song Y, et al. (2006) Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 48: 1688–1697.
[4]
Grieve DJ, Shah AM (2003) Oxidative stress in heart failure. More than just damage. Eur Heart J 24: 2161–2163.
[5]
Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS (2003) H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 35: 615–621.
[6]
Wold LE, Ceylan-Isik AF, Fang CX, Yang X, Li SY, et al. (2006) Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 40: 1419–1429.
[7]
Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J (2003) AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 42: 206–212.
[8]
Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, et al. (2007) Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56: 2457–2466.
[9]
Weyler W, Hsu YP, Breakefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47: 391–417.
[10]
Maurel A, Hernandez C, Kunduzova O, Bompart G, Cambon C, et al. (2003) Age-dependent increase in hydrogen peroxide production by cardiac monoamine oxidase A in rats. Am J Physiol Heart Circ Physiol 284: H1460–1467.
[11]
Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D, et al. (2005) Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 112: 3297–3305.
[12]
Saraiva RM, Minhas KM, Zheng M, Pitz E, Treuer A, et al. (2007) Reduced neuronal nitric oxide synthase expression contributes to cardiac oxidative stress and nitroso-redox imbalance in ob/ob mice. Nitric Oxide 16: 331–338.
[13]
Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, et al. (2006) Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 49: 1434–1446.
[14]
Guo Z, Xia Z, Jiang J, McNeill JH (2007) Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 292: H1728–1736.
[15]
Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, et al. (2004) Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37: 959–968.
[16]
Group. HPSC (2002) MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 23–33.
[17]
Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, et al. (2002) Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919–1927.
[18]
Finkel T (2003) Oxidant signals and oxidative stress. Curr Opin Cell Biol 15: 247–254.
[19]
Kowluru RA, Engerman RL, Kern TS (2000) Diabetes-induced metabolic abnormalities in myocardium: effect of antioxidant therapy. Free Radic Res 32: 67–74.
[20]
Cai L, Li W, Wang G, Guo L, Jiang Y, et al. (2002) Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51: 1938–1948.
[21]
Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, et al. (2001) IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50: 1414–1424.
[22]
Nishio Y, Kashiwagi A, Taki H, Shinozaki K, Maeno Y, et al. (1998) Altered activities of transcription factors and their related gene expression in cardiac tissues of diabetic rats. Diabetes 47: 1318–1325.
[23]
Cnop M, Hannaert JC, Grupping AY, Pipeleers DG (2002) Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 143: 3449–3453.
[24]
El-Assaad W, Buteau J, Peyot ML, Nolan C, Roduit R, et al. (2003) Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology 144: 4154–4163.
[25]
Modesti A, Bertolozzi I, Gamberi T, Marchetta M, Lumachi C, et al. (2005) Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. Diabetes 54: 394–401.
[26]
Michiels C, Raes M, Toussaint O, Remacle J (1994) Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 17: 235–248.
[27]
Westermann D, Rutschow S, Jager S, Linderer A, Anker S, et al. (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56: 641–646.
[28]
Tschope C, Walther T, Escher F, Spillmann F, Du J, et al. (2005) Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 19: 2057–2059.
[29]
Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, et al. (2007) Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56: 1834–1841.
[30]
Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, et al. (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067–2072.
[31]
Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543–1553.
[32]
Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, et al. (2004) Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 143: 41–51.
[33]
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, et al. (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27: 1201–1206.
[34]
Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, et al. (2000) The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537–544.
[35]
Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, et al. (2006) Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 291: H2504–2514.
[36]
Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434–444.
[37]
McCord JM, Roy RS, Schaffer SW (1985) Free radicals and myocardial ischemia. The role of xanthine oxidase. Adv Myocardiol 5: 183–189.
[38]
Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, et al. (1999) The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 10: 157–167.
[39]
Baldwin AS Jr (2001) Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107: 3–6.
[40]
Rahman I, MacNee W (2000) Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med 28: 1405–1420.
[41]
Maziere C, Maziere JC (2009) Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic Biol Med 46: 127–137.
[42]
Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG (2009) The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol 8: 8.
[43]
Jiang Q, Liu P, Wu X, Liu W, Shen X, et al. (2011) Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol Cell Endocrinol 331: 34–40.
[44]
Riad A, Du J, Stiehl S, Westermann D, Mohr Z, et al. (2007) Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus. Eur J Pharmacol 569: 204–211.
[45]
Sen CK, Packer L (1996) Antioxidant and redox regulation of gene transcription. FASEB J 10: 709–720.
[46]
Rajavashisth TB, Yamada H, Mishra NK (1995) Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B. Arterioscler Thromb Vasc Biol 15: 1591–1598.
[47]
Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141–179.
[48]
Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T (1992) Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 176: 1583–1593.
[49]
Lavrovsky Y, Schwartzman ML, Levere RD, Kappas A, Abraham NG (1994) Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene. Proc Natl Acad Sci U S A 91: 5987–5991.
[50]
Turkseven S, Kruger A, Mingone CJ, Kaminski P, Inaba M, et al. (2005) Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. Am J Physiol Heart Circ Physiol 289: H701–707.
[51]
Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10: 2247–2258.
[52]
Schrammel A, Koesling D, Schmidt K, Mayer B (2000) Inhibition of purified soluble guanylyl cyclase by L-ascorbic acid. Cardiovasc Res 47: 602–608.
[53]
Mercurio F, Manning AM (1999) NF-kappaB as a primary regulator of the stress response. Oncogene 18: 6163–6171.
